IRVING, Texas, Oct. 6, 2025 — McKesson Corporation has released new insights highlighting the rapid growth and expanding infrastructure supporting cell and gene therapies (CGTs) in the United States. As the number of approved and investigational therapies continues to surge, McKesson is strengthening its role in connecting innovative treatments to patients through advanced logistics, regulatory alignment, and real-world delivery systems.
Science Significance
Cell and gene therapies represent a revolution in biomedical science, offering curative potential for rare and chronic diseases by targeting their root genetic causes. McKesson’s latest report emphasizes the importance of precision-controlled logistics, cryogenic storage, and real-time traceability to preserve the viability of these living therapies. These advancements ensure that cell-based and gene-edited products maintain potency and integrity from the manufacturing facility to the point of care, underscoring McKesson’s pivotal role in the scientific ecosystem.
Regulatory Significance
The rapid growth of the CGT sector has prompted regulators such as the U.S. FDA and EMA to evolve frameworks for advanced therapy medicinal products (ATMPs). McKesson’s compliance infrastructure mirrors these expectations, integrating Good Distribution Practice (GDP) and cGxP standards into every step of the supply chain. This ensures traceability, quality assurance, and patient safety, helping manufacturers meet regulatory and post-approval obligations efficiently. By supporting robust compliance, McKesson contributes to a more reliable and transparent therapeutic landscape.
Business Significance
Advertisement
The global CGT market is projected to exceed $45 billion by 2030, and McKesson’s investments in distribution innovation and commercialization services position it as a leader in this next-generation healthcare sector. The company’s expansion includes real-time data integration, reimbursement solutions, and manufacturer collaboration programs, enabling faster market entry for novel therapies. These strategic initiatives reinforce McKesson’s commitment to accelerating commercialization pathways and ensuring economic sustainability for biopharma developers and healthcare providers.
Patients’ Significance
For patients, the rise of CGTs represents life-changing progress. Individuals with conditions such as leukemia, hemophilia, and spinal muscular atrophy now have access to treatments offering durable remission or potential cure. McKesson’s enhanced logistics and distribution network help ensure these therapies reach patients safely, swiftly, and consistently, minimizing treatment delays. By addressing operational barriers, McKesson empowers more patients to benefit from precision medicine innovations that improve both survival and quality of life.
Policy Significance
As the CGT landscape expands, policymakers face growing challenges in reimbursement, equitable access, and data governance. McKesson’s leadership supports initiatives that promote affordability, sustainability, and regulatory transparency in advanced therapeutics. Collaborating with healthcare agencies and payers, McKesson advocates for evidence-based policies that enable timely adoption of groundbreaking treatments while ensuring system-wide value.
The 2025 McKesson report underscores a defining moment for advanced therapeutics. By combining logistics excellence, regulatory expertise, and patient-centered delivery, McKesson is helping turn the promise of cell and gene therapies into an achievable standard of care—ensuring that innovation reaches every patient who stands to benefit.
Source: InspiroGene by McKesson press release
